Peptidoglycan monomerAlternative Names: PGM
Latest Information Update: 17 Feb 2003
At a glance
- Originator Unknown
- Developer Aidan; BioPulse International [CEASED]; Nonindustrial source
- Mechanism of Action Angiogenesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Feb 2003 Discontinued - Clinical-Phase-Unknown for Cancer in Mexico (unspecified route)
- 17 Feb 2003 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 29 Aug 2000 New profile